Experience of using Alpha Normix in the treatment of antibiotic-associated diarrhea
DOI:
https://doi.org/10.32782/2077-6594/2024.3/18Keywords:
Alpha Normix, Enterol, antibiotic-associated diarrheaAbstract
Purpose of the study is to evaluate the efficacy and safety of Alfa Normix in the treatment of patients with antibiotic-associated diarrhea. Materials and methods. The study included 25 patients – 15 women and 10 men aged 30 to 60 years, with a duration of the disease of 1–2 months, who were divided into 2 groups depending on the treatment. The first group included 13 patients treated with probiotic therapy (Enterol 250 mg), the second group consisted of 12 patients in the complex therapy of which the drug Alpha Normix 250 mg with probiotic was used. All examined patients had manifestations of diarrhea, intoxication and dyspeptic syndromes. The inclusion criteria for the study were clinical and laboratory methods to confirm the diagnosis, including: a complete blood count, an extended biochemical analysis. The method of determining the presence of an infectious agent in the body of the subjects was the qualitative determination of the antigen in the feces of Clostridium difficile (toxin A/B). Results. According to the study and assessment of the patients’ condition on the 5th day after the start of drug therapy, in the group of patients treated with Alfa Normix 200 mg in combination with a probiotic, the general condition improved significantly, the severity of diarrhea, dyspeptic and intoxication syndromes decreased, compared with the group treated with a probiotic alone (Enterol 250 mg), and a slight positive trend was observed. Conclusions. The increase in the incidence of antibiotic-associated diarrhea in patients who have received long-term antibiotic therapy leads to a number of complications, including the development of pseudomembranous colitis. The results obtained from the clinical observation of 25 patients with antibiotic-associated diarrhea prove that the antimicrobial component of Alpha Normix effectively reduces the duration and severity of clinical manifestations of this disease, is safe to use and prevents the development of possible complications.
References
Beaugerie L, Petit JC. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best practice & research. Clinical gastroenterology. 2004; 18 (2): 337–352. DOI: 10.1016/j. bpg.2003.10.002.
Скрипник ІМ, Приходько НП. Антибіотикоасоційована діарея: роль пробіотиків у лікуванні та профілактиці. Український медичний часопис. 2021; 2 (142): 1–5. DOI: 10.32471/umj.1680-3051.142.203410.
Анохіна ГА. Антибіотик-асоційована діарея: особливості вибору пробіотика, доза та тривалість лікування. Український терапевтичний журнал. 2020; 1: 62–66. DOI: 10.30978/UTJ2020-1-62.
Gazzola A, Panelli S, Corbella M, Merla C, Comandatore F, De Silvestri A, Piralla A, Zuccaro V, Bandi C, Marone P, Cambieri P. Microbiota in Clostridioides difficile-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections. Biomedicines. 2020 Sep 8; 8 (9): 335. DOI: 10.3390/biomedicines8090335.
Klem F, Wadhwa A, Prokop LJ. et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis. Gastroenterology. 2017; 152: 1042–1054. DOI: 10.1053/j.gastro.2016.12.039.
Welfare MR., Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect. 2011 Dec; 79 (4): 359–63. DOI: 10.1016/j.jhin.2011.08.015.
Sinnathamby ES, Mason JW, Flanagan CJ, Pearl NZ, Burroughs CR, De Witt AJ, Wenger DM, Klapper VG, Ahmadzadeh S, Varrassi G, Shekoohi S, Kaye AD. Clostridioides difficile Infection: A Clinical Review of Pathogenesis, Clinical Considerations, and Treatment Strategies. Cureus. 2023 Dec 27. 15 (12): e51167. DOI: 10.7759/cureus.51167.
Kukla M. Adrych K, Dobrowolska A. et al. Guidelines for Clostridium difficile infection in adults. Prz Gastroenterol. 2020; 15 (1): 1–21. DOI: 10.5114/pg.2020.93629.9.
McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008 Oct; 3 (5): 563–78. DOI: 10.2217/17460913.3.5.563.
Spigaglia P, Mastrantonio P, Barbanti F. Antibiotic Resistances of Clostridium difficile. Adv Exp Med Biol. 2018; 1050: 137–159. DOI: 10.1007/978-3-319-72799-8_9.
Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014 Jan . 8 (1): 1–6. DOI: 10.5009/gnl.2014.8.1.1.
Кривенко ВІ, Качан ІС, Федорова ОП, Кечеджиєва АВ, Пахомова СП. Складності діагностики антибіотик-асоційованої діареї на прикладі клінічного випадку. Запорізький медичний журнал. 2023; 25 (140): 472–476. DOI: 10.14739/2310-1210.2023.5.283350.
Elliott B, Androga GO, Knight DR, Riley TV. Clostridium difficile infection: Evolution, phylogeny and molecular epidemiology. Infect Genet Evol. 2017 Apr; 49: 1–11. DOI: 10.1016/j.meegid.2016.12.018.
Kachrimanidou M, Sarmourli T, Skoura L, Metallidis S, Malisiovas N. Clostridium difficile infection: New insights into therapeutic options. Crit Rev Microbiol. 2016 Sep; 42 (5): 773–9. DOI: 10.3109/1040841X.2015.1027171.
Yang H, Cai R, Zhang Y, Chen Y, Gu B. Gold Nanoclusters as an Antibacterial Alternative Against Clostridium difficile. Int J Nanomedicine. 2020 Aug 25; 15: 6401–6408. DOI: 10.2147/IJN.S268758.
